Kenneth G. Bensch

Oncology

3710 SW US Veterans Hospital Rd
Portland, OR 97239

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 08, 2023

Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.

Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.

Journal: Cancer medicine

Published: December 28, 2022

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications.

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications.

Journal: Cancers

Published: December 21, 2021

Prophylactic Aortic Stent Prevents Massive Hemorrhage and Hematemesis After Definitive Esophageal Chemoradiation in a Patient With Pretreatment Aortic Involvement.

Prophylactic Aortic Stent Prevents Massive Hemorrhage and Hematemesis After Definitive Esophageal Chemoradiation in a Patient With Pretreatment Aortic Involvement.

Journal: Practical radiation oncology

Published: February 21, 2019

Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.

Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Published: October 02, 2016

Showing 1-5 of 5

Last Updated: 09/26/2026